Apogee Therapeutics, Inc.
Business
Apogee Therapeutics is a clinical-stage biotechnology company developing optimized monoclonal antibodies targeting inflammatory and immunology indications including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company's pipeline comprises zumilokibart (APG777, anti-IL-13), APG279 (zumilokibart + APG990 anti-OX40L), APG273 (zumilokibart + APG333 anti-TSLP), and APG808 (anti-IL-4Rα), all engineered with extended half-life technology. All product candidates are in clinical development with no approved products marketed; manufacturing and supply are outsourced to contract manufacturers including WuXi Biologics and Samsung Biologics.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 215 | 168 | 68 | 28 | |
| General and administrative | 71 | 49 | 25 | 3 | |
| Total operating expenses | 286 | 217 | 93 | 31 | |
| Loss from operations | −286 | −217 | −93 | −31 | |
| Interest income, net | 30 | 35 | 9 | 92,000 | |
| Total other income, net | 30 | 35 | 9 | −9 | |
| Net loss before taxes | −256 | −182 | −84 | — | |
| Provision for income taxes | −278,000 | −18,000 | 0 | — | |
| Net loss after taxes | −256 | −182 | −84 | −40 | |
| Net loss per share, basic | −4.22 | −3.3 | −3.36 | −16.16 | |
| Net loss per share, diluted | −4.22 | −3.3 | −3.36 | −16.16 | |
| Weighted-average common shares outstanding, basic | 61 | 55 | 25 | 2 | |
| Weighted-average common shares outstanding, diluted | 61 | 55 | 25 | 2 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-01-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 132 | 142 | 118 | 152 | — | |
| Marketable securities | 599 | 379 | 277 | — | — | |
| Prepaid expenses and other current assets | 11 | 9 | 3 | 165,000 | — | |
| Total current assets | 741 | 530 | 398 | 152 | — | |
| Long-term marketable securities | 173 | 210 | — | — | — | |
| Property and equipment, net | 6 | 2 | 377,000 | — | — | |
| Right-of-use asset, net | 9 | 11 | 2 | — | — | |
| Other non-current assets | 9 | 498,000 | 401,000 | — | — | |
| Total assets | 937 | 754 | 401 | 152 | — | |
| Accounts payable | 1 | 1 | 2 | 418,000 | — | |
| Lease liability | 4 | 3 | 1 | — | — | |
| Accrued expenses and other current liabilities | 23 | 24 | 17 | — | — | |
| Total current liabilities | 28 | 29 | 21 | 10 | — | |
| Lease liability, net of current | 5 | 9 | 933,000 | — | — | |
| Total liabilities | 33 | 37 | 21 | 10 | — | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Common Stock; $0.00001 par value, 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 2025; 400,000,000 authorized, 59,478,725 issued and 58,062,898 outstanding as of December 31, 2024 | 1,000 | 1,000 | — | — | — | |
| Additional paid-in capital | 1,465 | 1,022 | 503 | — | — | |
| Accumulated other comprehensive income | 1 | 915,000 | 329,000 | — | — | |
| Accumulated deficit | −562 | −306 | −124 | −40 | — | |
| Total stockholders' equity | 904 | 717 | 380 | −35 | 0 | |
| Total liabilities and stockholders' equity | 937 | 754 | 401 | 152 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Net loss | −256 | −182 | −84 | −40 | |
| Depreciation expense | 1 | 200,000 | — | — | |
| Equity-based compensation expense | 46 | 23 | 6 | 2 | |
| Amortization of discounts on marketable securities | −8 | −12 | −3 | — | |
| Non-cash lease expense | 4 | 2 | 87,000 | — | |
| Prepaid expenses and other current assets | −2 | −6 | −3 | −165,000 | |
| Other assets | −8 | −97,000 | −107,000 | — | |
| Accounts payable | 150,000 | −1 | 2 | 418,000 | |
| Operating lease liability | −4 | −1 | −270,000 | — | |
| Accrued expenses | −1 | 6 | 8 | 10 | |
| Net cash used in operating activities | −228 | −171 | −75 | −16 | |
| Purchases of marketable securities | −642 | −649 | −304 | — | |
| Maturities of marketable securities | 468 | 350 | 30 | — | |
| Purchases of property and equipment | −5 | −1 | −167,000 | — | |
| Net cash used in investing activities | −180 | −300 | −274 | — | |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | 324 | 450 | 315 | — | |
| Proceeds from issuance of common stock under ATM equity offering program, net of issuance costs | 66 | 44 | — | — | |
| Proceeds from exercise of options and employee stock purchase plan purchases | 7 | 2 | — | — | |
| Net cash provided by financing activities | 396 | 495 | 315 | 168 | |
| (Decrease) increase in cash, cash equivalents and restricted cash | −11 | 23 | −33 | 152 | |
| Exchange of 72,636,636 preferred, common, and incentive units in connection with the Reorganization (Note 1) | — | — | 184 | — | |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | 999,000 | 11 | 2 | — | |
| Deferred financing issuance costs in accounts payable and accrued expenses | — | 30,000 | — | — | |
| Purchases of property and equipment included in accounts payable and accrued expenses | — | 619,000 | 210,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Apogee Therapeutics, Inc.'s CIK number?
Apogee Therapeutics, Inc.'s SEC CIK number is 0001974640 (1974640). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Apogee Therapeutics, Inc.'s SEC filings?
All of Apogee Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Apogee Therapeutics, Inc. last report earnings?
Apogee Therapeutics, Inc. (APGE) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-215683). This is Apogee Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Apogee Therapeutics, Inc.'s most recent earnings 8-K?
Apogee Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-215683. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Apogee Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →